<DOC>
	<DOCNO>NCT00002961</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy , radiation therapy , bone marrow transplantation may kill cancer cell . PURPOSE : Randomized phase III trial compare high-dose chemotherapy without total-body irradiation bone marrow transplantation treat child acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Chemotherapy With Without Total-Body Irradiation Prior Bone Marrow Transplantation Treating Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy busulfan contain condition regimen versus total body irradiation ( TBI ) contain regimen child acute lymphoblastic leukemia ( ALL ) undergo allogeneic bone marrow transplantation . II . Compare relapse rate chemotherapy regimen versus total body irradiation contain regimen child ALL . III . Assess compare acute chronic neuropsychological effect bone marrow transplantation ( BMT ) child undergo BMT busulfan TBI conditioning regimen . IV . Assess compare cardiac , pulmonary growth effect BMT child undergo condition regimen . V. Assess relationship plasma busulfan level relapse toxicity . VI . Assess compare minimal residual disease pattern quantitative polymerase chain reaction ( PCR ) patient receive busulfan TBI conditioning regimen . OUTLINE : This multicenter , randomize study compare chemotherapy arm , include busulfan , TBI contain arm . Arm I patient receive TBI day -7 , -6 , -5 give 2 fraction daily . Arm II patient receive busulfan every 6 hour day -8 , -7 , -6 , -5 . Both regimen follow etoposide 4 hour day -4 cyclophosphamide intravenously ( IV ) day -3 -2 . Marrow infusion begin follow day rest . Starting day -1 , cyclosporine IV administer every 12 hour continuous infusion continue day 50 . Methotrexate IV administer day 1 , 3 , 6 PROJECTED ACCRUAL : A total 230 patient enter study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm childhood acute lymphoblastic leukemia ( ALL ) second hematologic remission great relapse : On therapy OR Within one year discontinuation therapy OR Greater 1 year discontinuation high risk intensive therapy ( match sibling donor ) Patients central nervous system testicular relapse : Occurred within 18 month diagnosis OR Following prophylactic therapeutic cranial irradiation T cell disease isolated central nervous system ( CNS ) bone marrow relapse time Patients first remission great 4 week achieve remission high risk feature : ( 4,11 ) ( 9,22 ) Hypodiploidy Patients 12 month age first remission follow feature diagnosis : CALLA ( CD10 ) negative white blood count ( WBC ) least 100,000/mm3 Day 14 M2 M3 bone marrow CNS disease PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No active hepatitis B C Bilirubin great 1.5 time normal Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less 2.5 time normal Renal : Creatinine great 1.5 time normal OR Creatinine clearance least 65 mL/min Cardiovascular : Shortening fraction great 27 % echocardiogram OR Ejection fraction great 47 % radionuclide angiogram Pulmonary : [ 1 ] forced expiratory volume one second ( FEV1 ) /forced vital capacity ( FVC ) great 60 % For uncooperative child : No evidence dyspnea rest No exercise intolerance Pulse oximetry great 94 % Other : No active infection No occult untreated infection HIV negative Not eligible Children 's Cancer Group ( CCG ) Pediatric Oncology Group ( POG ) transplant study Donor criterion : Genotypically match sibling phenotypically match family member ( bone marrow peripheral blood stem cell may use ) One antigen mismatch related donor Matched one antigen mismatch unrelated donor Cord blood ( genotypic phenotypic match one antigen mismatch ) Matched sibling phenotypically match family member peripheral stem cell PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
</DOC>